Conference Coverage

Rivaroxaban bonus: Early unmasking of occult GI cancers


 

REPORTING FROM THE ESC CONGRESS 2018


In contrast, the incidence of non-GI cancer following a GI bleed was 1.5%, while the rate was 1.0% in patients with no prior GI bleeding.

“That relationship was much weaker, with an odds ratio of 1.77, indicating that the relationship between GI bleeding and GI cancer is not only very strong but it’s rather specific,” according to Dr. Eikelboom.

Of GI cancers associated with a prior major GI bleed, 77% were diagnosed within 6 months following the bleed, as were nearly 89% of GU cancers. Another 9%-10% were diagnosed 6-12 months after the bleeding event.

“The implication for clinical practice is certainly that in patients who have GI or GU bleeding while receiving antithrombotic therapy, we should conduct a vigorous search for underlying cancer in the same organ system,” he concluded.

Discussant Lars C. Wallentin, MD, concurred. He called it a wake-up call for cardiologists to broaden their horizons and recognize that their elderly patients with vascular disease also are at substantial competing risk for major noncardiovascular diseases – and that his colleagues may have an important role to play in earlier cancer diagnoses.

Pages

Recommended Reading

DOACs found safer than warfarin in the real world
MDedge Cardiology
How to identify DVT faster in pediatric osteomyelitis
MDedge Cardiology
No benefit of direct stenting in PCI
MDedge Cardiology
Guideline: PFO closure best bet for recurrent stroke prevention
MDedge Cardiology
Blood pressure control prevents cognitive impairment
MDedge Cardiology
VTE risk unchanged by rivaroxaban after discharge
MDedge Cardiology
Rivaroxaban superior to aspirin for extended VTE treatment
MDedge Cardiology
New stroke intervention guidelines stress volume
MDedge Cardiology
Think DEB, not BMS, with high bleeding risk
MDedge Cardiology
Expert panel updates guidelines on antithrombotic therapy for AF
MDedge Cardiology